Overview

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Status:
Completed

Trial end date:
2017-01-04

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Collaborator:

UCB Pharma

Treatments:

Cytarabine
Fludarabine
Fludarabine phosphate
Inotuzumab Ozogamicin
Mitoxantrone